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Background: Erythropoietin-producing hepatocellular (Eph) receptor, consisting of a family of receptor tyrosine
kinases, plays critical roles in tumour development and is considered an attractive target for cancer therapy.
Methods: Tumour samples were obtained from 222 patients with gastric adenocarcinoma who underwent
gastrectomy. The expressions of EphA2, EphA4, and ephrinA1 were evaluated immunohistochemically.
Results: High expressions of EphA2, EphA4, and ephrinA1 significantly correlated with variables related to tumour
progression, including the depth of invasion, metastatic lymph nodes, pathological stage, and distant metastasis or
recurrent disease. High expressions of EphA2, EphA4, and ephrinA1 were significantly associated with poorer
disease-specific survival (DSS; p < 0.001, p < 0.001, p = 0.026). On multivariate analysis, EphA4 was an independent
prognostic factor of DSS (hazard ratio [HR], 2.3; 95% confidence interval [CI], 1.1-4.8; p = 0.028), and EphA2 tended
to be a prognostic factor (HR, 2.4; 95% CI, 1.0-5.8; p = 0.050). In stage II and III cancer, EphA4 and EphA2 were both
significantly associated with shorter survival (p = 0.007 and 0.019), but only EphA2 was an independent prognostic
factor (HR, 2.6; 95% CI, 1.1-6.3; p = 0.039).
Conclusion: EphA4 may play important roles in tumor progression and outcomes in patients with gastric cancer.
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Gastric cancer is the fourth most common malignancy
and the second leading cause of death in the world [1].
The outcomes of gastric cancer remain poor, with an es-
timated relative 5-year survival rate of 25% in Europe
[2]. At present, the treatment of choice for gastric cancer
is complete surgical removal of the tumour and adjacent
lymph nodes. However, even after macroscopic complete
removal of the primary tumour and metastatic lymph
nodes, many patients with advanced disease have recur-
rence. The effectiveness of therapeutic approaches such
as chemotherapy, hormonal therapy, and radiotherapy
remains very limited. Although combination chemother-
apy regimens consisting of two or three cytotoxic agents
have been developed, overall survival is 10 to 13 months
in patients with unresectable or metastatic gastric cancer
who receive chemotherapy [3,4]. Many receptor tyrosine
kinases (RTKs) have been shown to be related to tumour
progression and patient outcomes in various cancers.
RTK inhibitors such as human epidermal growth factor* Correspondence: m-inokuchi.srg2@tmd.ac.jp
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reproduction in any medium, provided the orreceptor (HER) have been evaluated, and some have been
used to treat gastrointestinal cancers. Only trastuzumab, a
monoclonal antibody against the p185HER2 protein, is
now used clinically to treat unresectable or metastatic gas-
tric cancers with HER2 overexpression. However, only
12% of patients with far advanced gastric cancer respond
to trastuzumab, and the median survival time was only 16
months in patients with HER2-positive tumours who re-
ceived chemotherapy with trastuzumab [5]. Other mole-
cules associated with patient survival have therefore been
investigated to identify potential targets for chemotherapy.
Erythropoietin-producing hepatocellular (Eph) receptors
represent the largest known family of RTKs and are acti-
vated by interacting with cell-surface ligands, termed
ephrins. Eph receptors are classified into A-type (EphA1-8
and EphA10) and B-type (EphB1-4 and EphB6) according
to their interactions with ephrin ligands, which are also
classified into A-type and B-type [6]. Eph receptors and
ephrin ligands control cell morphology, adhesion, migra-
tion, and invasion by modifying the organization of the
actin cytoskeleton and influencing the activities of integrins
and intercellular adhesion molecules [7]. Combinations of
Eph receptors and ephrin ligands are thought to occur in a
tissue-type or cancer-type specific manner. In malignantl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vating downstream signaling pathways. The up-regulation
of Eph and ephrin has been reported in various types of
cancer. Altered expression patterns of Eph and ephrin cor-
relate with tumour-promoting features such vascularization
and epithelial-mesenchymal transition [8]. In gastric cancer,
overexpression of EphA2, A4, and ephrinA1 has been
reported by a few small studies [9,10]. We therefore exam-
ined the relation between clinical outcomes and immuno-




The study group comprised 222 patients with primary
gastric adenocarcinomas who underwent surgery fromFigure 1 Immunostaining for EphA2, EphA4, and ephrinA1. Represent
immunostaining for EphA2 (A), EphA4 (B), and ephrinA1 (C). Representative
intensity scores of 1 (D), 2 (E), and 3 (F), immunostaining for EphA4 with in
ephrinA1 with intensity scores of 0 (J) and 3 (K). Positive control for ephrin
lymph nodes showing immunostaining for EphA2 (M), EphA4 (N), and eph
staining of EphA4 in one tumor (P); magnification, 20×. The upper and low
magnification, 200 × .January 2003 through December 2007 at the Department
of Esophagogastric Surgery, Tokyo Medical and Dental
University. This study was conducted in accordance with
the Declaration of Helsinki [11] and approved by the In-
stitutional Review Board of Tokyo Medical and Dental
University. Written Informed consent was obtained from
all patients in this study. Each tumour was classified
according to the tumour-node-metastasis (TNM) system
recommended by the International Union against Can-
cer. Of the 222 patients, 168 were male and 54 were fe-
male. The mean age was 64.6 years (range: 21-92 years).
All patients were evaluated for recurrent disease by
tumour-marker analysis or diagnostic imaging (com-
puted tomography, ultrasonography, magnetic resonance
imaging, and endoscopy) every 3 to 6 months. Patients
with distant metastatic or recurrent disease receivedative normal gastric epithelium and stromal cells showing no or weak
primary gastric carcinomas showing immunostaining for EphA2 with
tensity scores of 1 (G), 2 (H), and 3 (I), and immunostaining for
A1 in breast cancer tissue is shown (L). Representative metastatic
rinA1 (O). Magnification, 400× (A-L), 200× (M-O), Heterogeneous
er insets show EphA4 with intensity scores of 1 and 3, respectively;
Table 2 Correlations of EphA2, EphA4, and ephrinA1
between primary tumour and metastatic lymph nodes
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apy. Twenty patients (9%) received adjuvant chemotherapy
with S-1 after radical resection. All patients were followed
up until July 2012. The median follow-up was 60 months
(3-111). A total of 77 (35%) patients died, 66 (30%) had re-
current disease, and 11 (5%) died of other causes.
Immunohistochemical analysis of EphA2, EphA4, and
ephrinA1 proteins
For immunohistochemical analysis, immunostaining was
carried out with the use of a peroxidase-labeled polymer
conjugated to secondary antibodies (Histofine Simple
Stain MAX PO [MULTI], Nichirei Co., Tokyo, Japan).
Polyclonal rabbit antibodies against Eph A2 (C-20, sc-
924), Eph A4 (S-20, sc-921), and ephrin-A1 (V-18, sc-
911) were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA, U.S.A.). These antibodies have
been used in other studies [9,12-14], and the specificities
of EphA2 and ephrinA1 antibodies were demonstrated
by immunoadsorption tests or Western blotting (exclud-
ing EphA4) [13,14]. All available hematoxylin-and-eosin-
stained slides of the surgical specimens were reviewed.
For each case, representative paraffin blocks were se-
lected for immunohistochemical studies. Three-
micrometer-thick sections were cut from formalin-fixed,
paraffin-embedded tissue blocks. After deparaffinization
and rehydration, antigen retrieval treatment was carried
out at 98°C (microwave processor, MI-77, AZUMAYA,
Tokyo, Japan) for 20 min in pH 6.0, 10 mmol/L sodium
citrate buffer (Mitsubishi Chemical Medience Corpor-
ation, Tokyo, Japan). Endogenous peroxidase was
blocked with 3% hydrogen peroxide in methanol.
Nonspecific binding was then blocked by treating the
slides with 10% normal goat serum for 10 min at room
temperature. The slides were incubated with primary
antibodies including Eph A2 (dilution 1:100), Eph A4
(1:150), and ephrinA1 (1:200) in 1% BSA/PBS(-) over-
night at 4°C. Sections were incubated with Simple Stain
Max PO (MULTI) for 30 min. After three additional
washes, 3,3′-diaminobenzidine tetrahydrochloride solu-
tion (Histofine Simple Stain DAB Solution, Nichirei Co.,Table 1 Correlations among expressions of EphA2,
EphA4, and ephrinA1
EphA4 ephrinA1





high 52 93 54 91
EphA4
low 76 35 <0.001
high 31 80Tokyo, Japan) was applied. Sections were then
counterstained with Mayer’s hematoxylin (WAKO,
Tokyo, Japan). Negative controls were treated similarly,
except that the antibodies were replaced by normal
rabbit IgG (Santa Cruz Biotechnology, Inc.). Breast can-
cer tissues served as positive controls.
Interpretation of the immunostaining results
Staining intensity was scored into four grades: 0 (none),
1 (weakly positive), 2 (moderately positive), and 3
(strongly positive). Staining extent (positive frequency)
was also scored into four grades according to the per-
centage of stained tumour cells: 0 for complete absence
of staining, 1 for <20%, 2 for 20% to <50%, and 3 for
≥50% cells. Composite scores were derived by multiply-
ing the intensity score by the staining-extent score. For
statistical analysis, composite scores of ≥4 were defined
as high expression, and scores of <4 were considered
low expression. Two investigators (M.K. and T.Y.), who
were blinded to patients’ outcomes separately counted
stained cancer cells in at least three fields per section,
including the deepest site invaded by cancer cells, the
surface of the lesion, and an intermediate zone. Any dis-
agreements between the two investigators were resolved
by reassessment and consensus.
Statistical analysis
The χ2 test was used to test possible associations of Eph/
ephrin expression with clinicopathological variables. The
Mann-Whitney U-test was used to analyse the relation
between Eph/ephrin expression and patient age. Kaplan-
Meier curves were plotted to assess the effect of Eph/
ephrin expression on disease-specific survival (DSS). Dif-
ferent DSS curves were compared using the log-rank
test. Multivariate proportional Cox models were used to
assess the prognostic significance of Eph/ephrin and fac-
tors associated with DSS. P values of less than 0.05 were
considered to indicate statistical significance. StatisticalMetastatic lymph nodes
low high p
EphA2
low 8 12 0.87
high 27 44
EphA4
Primary low 14 12 0.012
tumor high 17 48
ephrinA1
low 21 15 0.85
high 31 24
Table 3 Correlations between the expression of EphA2, EphA4, and ephrinA1 and clinicopathological factors
EphA2 EphA4 ephrinA1
low high p low high p low high p
n 77 145 111 111 107 115
Age
<70 142 53 89 0.27 75 67 0.26 72 70 0.32
≥70 80 24 56 36 44 35 45
Gender
female 54 17 37 0.57 32 22 0.12 29 25 0.35
male 168 60 108 79 89 78 90
Main location
middle or lower 177 66 111 0.11 89 88 0.87 92 85 0.025
upper 45 11 34 22 23 15 30
WHO pathological type
differentiated 107 35 72 0.55 54 53 0.89 48 59 0.34
undifferentiated 115 42 73 57 58 59 56
Depth of invasion
T1/2 118 59 59 <0.001 85 33 <0.001 69 49 0.001
T3/4 104 18 86 26 78 38 66
Lymphatic invasion
negative 69 35 34 0.001 51 18 <0.001 47 22 <0.001
positive 153 42 111 60 93 60 93
Venous invasion
negative 73 39 34 0.001 55 18 <0.001 52 21 <0.001
positive 149 38 111 56 93 55 94
Lymph node metastasis
negative (N0) 114 54 60 0.001 77 37 <0.001 65 49 0.007
positive (N1/2/3) 108 23 85 34 74 42 66
Stage
I / II 142 66 76 <0.001 95 47 <0.001 80 62 0.001
III/IV 80 11 69 16 64 27 53
Distant metastasis or recurrence
negative 152 69 83 <0.001 99 53 <0.001 81 71 0.025
positive 70 8 62 12 58 26 44
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(IBM, Inc., Armonk, NY, U.S.A.).
Results
Immunohistochemistry of EphA2, EphA4, and ephrinA1
Expressions of EphA2, EphA4, and ephrinA1 were mainly
observed in the cytoplasm of cancer cells (Figure 1). Ex-
pression was also noted in lymphocytes and blood endo-
thelial cells in cancer tissue. Weak expression was found
in some regions of normal epithelium. High expression of
EphA2, EphA4, and ephrinA1 was found in 145 (65%),
111 (50%), and 115 (52%) patients, respectively. Thenumbers of patients with composite scores of 4, 5, and 6
were respectively 56 (25%), 72 (32%), and 17 (8%) for
EphA2, 8 (26%), 41 (18%), and 12 (5%) for EphA4, and 79
(36%), 32 (14%), and 4 (2%) for ephrinA1. High expression
of EphA2, EphA4, or ephrinA1 significantly correlated
with high expression of each of the other two proteins
(Table 1). On evaluation of 91 metastatic lymph nodes,
high expression of EphA2, EphA4, and ephrinA1 was
found in 56 (62%), 60 (66%), and 39 (43%) patients, re-
spectively. However, only EphA4 showed a significant re-
lation between expression in primary tumours and that in























































Figure 2 Survival of all patients. Kaplan-Meier curves for the
disease-specific survival of patients with expression of EphA2 (A),
EphA4 (B), and ephrinA1 (C) in the study group as a whole.
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Clinicopathological variables are shown in Table 3. High
expressions of EphA2, EphA4, and ephrinA1 were signifi-
cantly associated with the depth of tumour invasion (T3-
T4 versus T1-T2; p < 0.001, p < 0.001, and p = 0.001,
respectively), lymph node metastasis (p = 0.001, p < 0.001,
and p = 0.007, respectively), and tumour stage (III-IV versus
I-II; p < 0.001, p < 0.001, and p = 0.001, respectively).
Lymphatic and venous invasion were significantly associ-
ated with high expressions of EphA2, EphA4, and ephrinA1
(lymphatic invasion: p = 0.001, p < 0.001, and p < 0.001;
venous invasion: p < 0.001, p < 0.001, and p < 0.001, respect-
ively). Distant metastasis or recurrence was found in a sig-
nificantly higher proportion of patients with high
expressions of EphA2, EphA4, and ephrinA1 than in those
with low expressions of these proteins (p < 0.001, p < 0.001,
and p = 0.025, respectively).
Relationship to DSS
High expressions of EphA2, EphA4, and ephrinA1 were
significantly associated with poorer DSS on univariate
analysis (p < 0.001, p < 0.001, and p = 0.026, respectively,
Figure 2). The 5-year DSS was respectively 60%, 52%, and
65% in patients with high expression of EphA2, EphA4,
and ephrinA1, as compared with 92%, 90%, and 78% in
patients with low expression. EphA4 was an independent
predictor of DSS (HR, 2.3; 95% CI, 1.1-4.8; p = 0.028) on
multivariate Cox proportional-hazards regression analysis
(Table 4) adjusted for the following established clinical
prognostic factors: depth of tumour (T3-T4 versus T1-T2
), lymph node metastasis, and histopathological type (un-
differentiated versus differentiated). EphA2 showed a
trend toward being an independent prognostic factor (HR,
2.4; 95% CI, 1.0-5.8; p = 0.050).
Relationship to DSS in stage II and III disease
In patients with pathological stage II and III disease,
high expression levels of EphA2 and EphA4 were signifi-
cantly associated with poorer DSS on univariate analysis
(p = 0.019, p = 0.007, Figure 3). In contrast, ephrinA1
was unrelated to DSS (p = 0.39). The 5-year DSS was re-
spectively 52% and 49% in patients with high expression
of EphA2 and EphA4, as compared with 83% and 79% in
those with low expression. EphA4 was an independent
predictor of DSS on multivariate Cox proportional-
hazards regression analysis (HR, 2.6; 95% CI, 1.1-6.3;
p = 0.039, Table 5) adjusted for the following established
clinical prognostic factors: depth of tumour (T4 versus
T1-T3), lymph node metastasis, and histopathological
type. The depth of tumour invasion was classified into
T4 and T1-3 tumours in this limited population because
there were few T1 and T2 tumors, and the difference in
DSS was more statistically significant between T4 and
T1-3 than that between T3-4 and T1-2 on univariate
Table 4 Prognostic factors in univariate and multivariate Cox proportional-hazards regression models for disease-
specific survival in the study group as a whole
Univariate (Log-rank) Multivariate












undifferentiated 63 0.007 1.6 0.94-2.7 0.080
Depth of invasion
T1/2 95 1
T3/4 45 <0.001 4.2 1.6-11 0.003
Lymph node metastasis
negative 95 1
positive 47 <0.001 4.1 1.8-10 0.001
EphA2
low 92 1
high 60 <0.001 2.4 1.0-5.8 0.050
EphA4
low 90 1
high 52 <0.001 2.3 1.1-4.8 0.028
ephrinA1
low 78 1
high 65 0.026 0.88 0.50-1.5 0.64
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in stage II and III gastric cancer.
Discussion
Our results suggest that high expression of EphA4 and
EphA2 may play critical roles in tumor progression, me-
tastasis, and outcomes in gastric cancer. EphA4 was an in-
dependent prognostic factor in gastric cancer, even in
advanced disease requiring adjuvant chemotherapy after
resection to prevent recurrence. Our findings are consist-
ent with those of a previous study showing that
overexpression of EphA4 on immunohistochemical ana-
lysis is an independent predictor of overall survival in gas-
tric cancer [9]. Overexpression of the EphA4 gene in
colorectal primary tumors has been found to be associated
with liver metastasis, although expression levels of this
gene did not correlate with any other clinicopathologicalfactor and did not differ between cancer tissue and adja-
cent normal mucosa [10]. In breast cancer, elevated RNA
expression of EphA4 had significant prognostic value, as
did EphA2, EphA7, and EphB4 [15]. High gene expression
of EphA4 has been linked to overexpression of the protein
in gastric cancer [9], whereas EphA4 gene amplification
has not. Some activated signaling pathways seem to be in-
volved in tumour progression. Activated EphA4 and
EphA2 have been shown to trigger the activation of RhoA,
which ultimately led to reinitiation of migration in a differ-
ent direction in a prostate cancer cell line [16]. EphA4
forms a heteroreceptor complex with fibroblast growth
factor receptor 1 (FGFR1) in glioma cells, and the EphA4-
FGFR1 complex potentiates FGFR-mediated downstream
signaling [17]. EphA4-ephrinA3 pathway has been consid-
ered a promising target in pancreatic cancer cells [12].























































Figure 3 Survival of patients in stage II and III. Kaplan-Meier
curves for the disease-specific survival of patients with expression of
EphA2 (A), EphA4 (B), and ephrinA1 (C) who had stage II and
III disease.
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ligands (A1-A5), and EphB receptors bind to transmem-
brane ephrin-B ligands (B1-B3). In the present study,
other ligands for EphA4 (except for ephrinA1) were not
investigated. On the other hand, even tumor-suppressive
activation of EphA4 was evident in another study. EphA4
has been reported to inhibit downstream Rac, which pro-
motes cell migration, through chimaerin binding to
EphA4 in response to ephrinA1 stimulation [20].
EphA2 is thought to down-regulate cell growth and mi-
gration in normal epithelium [21]. Interestingly, EphA2 is
highly expressed in a variety of cancers, including breast
[22], lung [23], prostate [24], urinary bladder [25], ovarian
[26], esophageal [27], pancreatic [28], and colorectal cancer
[29]. Overexpression of EphA2 is associated with tumour
progression or poor patient survival. The expression of
ephrinA1, known to be a major ligand of EphA2, has been
studied in various cancers. Expressions of both EphA2 and
ephrinA1 on the basis of the mRNA level or immunohisto-
chemical analysis have been demonstrated to be higher in
gastric cancer than in normal tissue, and EphA2 was signifi-
cantly associated with poor survival, whereas ephrinA1 was
not [13]. EphrinA1 expression has been significantly associ-
ated with EphA2 expression, although ephrinA1 was not an
independent prognostic factor in several types of cancer
[27,30,31]. Our findings are in accord with the results of
these previous studies. In gastric cancer cell lines that ex-
press EphA2, stimulation of EphrinA1 decreases EphA2
protein expression, but increases EphA2 phosphorylation
[14]. Also in non-tumour cells, EphA2 was degraded by Cbl
binding to ephrinA1 [32]. On the other hand, expression of
EphA2 and ephrinA1 has been confirmed in both the vas-
culature and tumor cells in cancer tissues, and EphA2 might
be required for angiogenesis in an in vitro model [33]. The
interaction of Eph receptor and ephrin ligand expressed on
vasculature cells might be associated with angiogenesis in
tumours. In the present study, EphA2, ephrinA1, and even
EphA4 were also expressed in vascular endothelial cells
existing in cancer tissue.
Gene expression or quantitative assessment is important
and necessary to confirm the outcomes of this study, al-
though mRNA expression levels of EphA2, EphA4, and
ephrinA1 were shown to be higher in gastric cancer tissue
than in non-cancerous gastric tissue by other investigators
[9,13]. Many pathological and molecular assays suggest that
gastric cancer is a heterogeneous disease. Analysis of one
small part of a specimen by techniques such as tissue
microarray may not convey the entire picture of heteroge-
neous diseases such as gastric cancer, consisting of many
scattered tumour cells. Staining for EphA2, EphA4, and
ephrinA1 often differed between the lesion surface and sites
of deep invasive or between differentiated and undifferenti-
ated portions of the same sample in the present study. We
also evaluated the expressions of EphA2, EphA4, and
Table 5 Prognostic factors in univariate and multivariate Cox proportional-hazards regression models for disease-
specific survival in patients with stage II and III disease
Univariate (Log-rank) Multivariate
n 5-yr DSS(%) p HR 95%CI p
Age
<70 65 54
≥70 33 64 0.63
Gender
female 22 64
male 76 56 0.49
Main location
middle or lower 78 61
upper 20 44 0.24
WHO pathological type
differentiated 39 69 1
undifferentiated 59 50 0.077 1.7 0.86-3.3 0.13
Depth of invasion
T1-3 48 85 1
T4 50 32 <0.001 5.5 2.5-12 <0.001
Lymph node metastasis
negative 20 89 1
positive 78 49 0.004 3.0 0.92-9.9 0.070
EphA2
low 18 83 1
high 80 52 0.019 1.7 0.52-5.7 0.38
EphA4
low 28 79 1
high 70 49 0.007 2.6 1.1-6.3 0.039
ephrinA1
low 40 51
high 58 62 0.39
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Eph and ephrin in metastatic sites of gastric cancer have not
been investigated previously. Expressions of EphA2 and
ephrinA1 differed between primary tumor and lymph node
metastasis and correlated significantly with the expression
of only EphA4. This discrepancy may have been caused by
methodological issues, although gene analysis by extraction
from metastatic lymph nodes may be difficult owing to the
presence of scattered tumour cells in innumerable lympho-
cytes. Differences in EphA2 or ephrinA1 expression among
tumour sites can make chemotherapy against these molecu-
lar targets challenging.
Various molecules targeting Eph and ephrin have been
developed. A small molecule that inhibits binding of ephrin
to EphA2 and EphA4 has been identified [19], and such in-
hibitors might be effective against advanced or metastatic
gastric cancer. Small interfering RNA-mediated inhibitionof EphA2 has been reported to retard tumour growth and
inhibit metastasis in an in vivo study of pancreatic adenocar-
cinoma [34]. However, Eph and ephrin are known to have
bidirectional signaling in cancer cells. Therefore, EphA2 ag-
onists most likely enhance tumor suppressor signaling path-
ways and receptor degradation in cancer cells, but promote
tumour angiogenesis [8].
Conclusion
EphA4 plays an important role in tumour progression and
clinical outcomes, similar to EphA2, in patients with gastric
cancer. EphA4 is an independent prognostic factor in stage
II and III gastric cancer, stages that usually require adjuvant
chemotherapy. The expression of EphA4 in primary tu-
mours significantly correlated with that in metastatic lymph
nodes. EphA4 may be a promising target for monoclonal
antibody therapy in patients with gastric cancer.
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